NASDAQ · Biotechnology

Adverum Biotechnologies Inc. (ADVM)

Stock, pipeline and biotech catalyst intelligence

$4.36Price unavailableCached market snapshot

Market cap$96.3M

Cash$26.1M

Quarterly burn$28.1M

Pipeline assets2

Short float4.6%

Clinical portfolio

Adverum Biotechnologies Inc. Drug Pipeline

Showing 1 of 2

Asset	Indication	Stage	Milestone	Signals ?
Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept)	Wet age-related macular degeneration , Age-related macular degeneration, Eye disease	Phase 3	Jun 30, 2027	—

Continue with BioPharma ProUnlock 1 additional programs and complete development details.

Upcoming milestones

1 currently tracked

Jun 30, 2027

Phase 3

Wet age-related macular degeneration , Age-related macular degeneration, Eye disease

Data readout

Event details

Company profile

Adverum Biotechnologies Inc. is a biotechnology company in the healthcare sector.

Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.